NurOwn is a cell therapy commercialized by BrainStorm Cell Therapeutics, with a leading Pre-Registration program in Amyotrophic Lateral Sclerosis. According to Globaldata, it is involved in 8 clinical trials, of which 6 were completed, 1 is ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of NurOwn’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for NurOwn is expected to reach an annual total of $1.38 bn by 2036 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

NurOwn Overview

Debamestrocel (NurOwn) is under development for the treatment of neurodegenerative diseases such as Alzheimer's disease, amyotrophic lateral sclerosis (ALS), progressive multiple sclerosis (primary and secondary sclerosis), Parkinson’s disease (PD), Huntington's disease, peripheral nerve injury, Coronavirus Disease 2019 (COVID-19), acute respiratory distress syndrome and autism spectrum disorder. The therapy is administered by intramuscular and intrathecal routes. NurOwn is an autologous, adult stem cell therapy developed based on a differentiation method which reprograms bone marrow-derived mesenchymal stem cells (MSC) into highly specialized, neuron-supporting cells. It is developed based on NurOwn cell therapy platform.

BrainStorm Cell Therapeutics Overview

BrainStorm Cell Therapeutics, formerly Golden Hand Resources Inc, is a biotechnology company which develops autologous stem cell therapies for neurodegenerative diseases. Its pipeline mesenchymal stem cell products are being developed based on cell therapy platform NurOwn, customized for the treatment of multiple sclerosis, amyotrophic lateral sclerosis, parkinson’s disease, huntington’s disease, autism spectrum disorder, peripheral nerve injury and other indications. Its proprietary technology NurOwn induces mesenchymal stem cells to secrete high levels of neurotrophic factors to promote the survival of neurons. The company has operations in the US and Israel. BrainStorm Cell Therapeutics is headquartered in New York, the US.
The operating loss of the company was US$24.8 million in FY2022, compared to an operating loss of US$24.5 million in FY2021. The net loss of the company was US$24.3 million in FY2022, compared to a net loss of US$24.5 million in FY2021.

For a complete picture of NurOwn’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.